Shanghai Henlius Biotech, Inc. Class H (2696) Stock Statistics & Valuation Metrics

Shanghai Henlius Biotech, Inc. Class H has a market cap or net worth of HK$36.36B. The enterprise value is HK$30.72B.

Shanghai Henlius Biotech, Inc. Class H has 347,781,160 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shanghai Henlius Biotech, Inc. Class H’s return on equity (ROE) is 0.20 and return on invested capital (ROIC) is 8.45%.

The current PE Ratio of Shanghai Henlius Biotech, Inc. Class H is 39.1. Shanghai Henlius Biotech, Inc. Class H’s PEG ratio is -17.43.

In the last 12 months, Shanghai Henlius Biotech, Inc. Class H had revenue of 6.67B and earned 805.64M in profits. Earnings per share was 1.48.

In the last 12 months, operating cash flow was 1.76B and capital expenditures -233.65M, giving a free cash flow of 1.53B billion.

Shanghai Henlius Biotech, Inc. Class H pays an annual dividend of ―, resulting in a dividend yield of ―

Shanghai Henlius Biotech, Inc. Class H upcoming earnings date is Mar 20, 2026, TBA (Not Confirmed).

Shanghai Henlius Biotech, Inc. Class H as a current ratio of 0.71, with Debt / Equity ratio of 90.82%

In the past 12 months, Shanghai Henlius Biotech, Inc. Class H has paid -14.92M in taxes.

Shanghai Henlius Biotech, Inc. Class H EV to EBITDA ratio is 26.56, with an EV/FCF ratio of 35.93.

Shanghai Henlius Biotech, Inc. Class H has HK$972.50M in cash and marketable securities with HK$3.67B in debt, giving a net cash position of -HK$2.70B billion.

Gross margin is 74.66%, with operating margin of 12.26%, and net profit margin of 12.08%.

The average price target for Shanghai Henlius Biotech, Inc. Class H is HK$110.96, which is 11.43% higher than the current price. The consensus rating is Moderate Buy